# Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult Participants

> **NCT06920693** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Generate Biomedicines** · enrollment: 40 (estimated)

## Conditions studied

- Atopic Dermatitis (AD)

## Interventions

- **DRUG:** GB-7624
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06920693
- **Lead sponsor:** Generate Biomedicines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-27
- **Primary completion:** 2026-08-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06920693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06920693, "Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult Participants". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06920693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*